Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Thanh Chung Vu"'
Autor:
Sara Corvigno, Yuan Liu, Emine Bayraktar, Elaine Stur, Nazende Nur Bayram, Adrian Lankenau Ahumada, Supriya Nagaraju, Cristian Rodriguez-Aguayo, Hu Chen, Thanh Chung Vu, Yunfei Wen, Han Liang, Li Zhao, Sanghoon Lee, Gabriel Lopez-Berestein, Anil K. Sood
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-13 (2024)
Abstract Small RNAs (microRNAs [miRNAs] or small interfering RNAs [siRNAs]) are effective tools for cancer therapy, but many of the existing carriers for their delivery are limited by low bioavailability, insufficient loading, impaired transport acro
Externí odkaz:
https://doaj.org/article/087c961034464f26a8c8679bea773cfa
Autor:
Yuan Liu, Adrian Lankenau Ahumada, Emine Bayraktar, Paul Schwartz, Mamur Chowdhury, Sixiang Shi, Manu M. Sebastian, Htet Khant, Natalia de Val, Nazende Nur Bayram, Guodong Zhang, Thanh Chung Vu, Zuliang Jie, Nicholas B. Jennings, Cristian Rodriguez-Aguayo, Jody Swain, Elaine Stur, Lingegowda S. Mangala, Yutuan Wu, Supriya Nagaraju, Brooke Ermias, Chun Li, Gabriel Lopez-Berestein, Janet Braam, Anil K. Sood
Publikováno v:
Journal of Controlled Release. 357:472-483
Publikováno v:
Liver International
Background & Aims Infigratinib is a pan‐FGFR (fibroblast growth factor receptor) inhibitor that has shown encouraging activity in FGFR‐dependent hepatocellular carcinoma (HCC) models. However, long‐term treatment results in the emergence of res
Autor:
Thanh Chung Vu, Alan Huang, Thi Bich Uyen Le, Hung Huynh, Youzhen Wang, Huaixiang Hao, Aldo Prawira, Diana Graus Porta
Publikováno v:
Experimental & Molecular Medicine
Hepatocellular carcinoma (HCC) is a lethal cancer with limited therapeutic options, and standard therapy with sorafenib provides only modest survival benefits. Fibroblast growth factor 19 (FGF19) has been proposed as a driver oncogene, and targeting
Autor:
Septian Hartano, Philip Lee, Choon Hua Thng, Tong San Koh, Rebecca Zhi Wen Ho, Aldo Prawira, Way Cherng Chen, Hung Huynh, Xing Qi Teo, Anh Tran, Thanh Chung Vu, Thi Bich Uyen Le
Publikováno v:
Molecular imaging and biology. 23(1)
Overexpression of fibroblast growth factor receptor (FGFR) contributes to tumorigenesis, metastasis, and poor prognosis of hepatocellular carcinoma (HCC). Infigratinib—a pan-FGFR inhibitor—potently suppresses the growth of high-FGFR-expressing HC
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Rebecca Zhi Wen Ho, Boon Cher Goh, Thanh Chung Vu, Hung Huynh, Aldo Prawira, Thi Bich Uyen Le, Lingzhi Wang
Publikováno v:
International Journal of Molecular Sciences
Volume 21
Issue 24
International Journal of Molecular Sciences, Vol 21, Iss 9405, p 9405 (2020)
Volume 21
Issue 24
International Journal of Molecular Sciences, Vol 21, Iss 9405, p 9405 (2020)
The fibroblast growth factor (FGF) signaling cascade is one of the key signaling pathways in hepatocellular carcinoma (HCC). FGF has been shown to augment vascular endothelial growth factor (VEGF)-mediated HCC development and angiogenesis, as well as
Autor:
Rebecca Zhi Wen Ho, Eric Ming Hon Lee, Thi Bich Uyen Le, Aldo Prawira, Jun Hao Phua, Iris Jiu Hia Lim, Yusnita Binte Omar, Wendy Wan Li Chow, Thanh Chung Vu, Gee Keng Low, Hung Huynh, Kheng Wei Yeoh, Khee Chee Soo, Kok Ming Lee, Muhammad Zafrie Bin Saad, Mohamed Hakim Bin Mohd Nasir
Publikováno v:
Cancers
Volume 12
Issue 4
Cancers, Vol 12, Iss 872, p 872 (2020)
Volume 12
Issue 4
Cancers, Vol 12, Iss 872, p 872 (2020)
There is a need to improve the effectiveness of radiotherapy (RT) in hepatocellular carcinoma (HCC). Therefore, the purpose of this study was to explore the efficacy and toxicity of the anti-microtubule agent Vinorelbine as a radiosensitizer in HCC.